Phase II Study of Pazopanib Monotherapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors Abstract #643

Introduction: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NETs) are still limited. The anti-angiogenic approach in metastatic pancreatic NETs has shown promising results.
Aim(s): We therefore investigated the anti-tumor activity and safety profile of pazopanib, a multi-target drug with antiangiogenic activity in patients with metastatic GEP NETs.
Materials and methods: This was a non-randomized, open-labeled, single center phase II study. Pazopanib was orally administered at a dose of 800 mg daily continuously with a 28-day cycle. The primary end point was an objective response rate according to RECIST version 1.1. The secondary endpoints were progression-free survival, overall survival and safety. An independent review of objective response was planned. Correlative biomarker analyses were performed.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Others
Presenting Author: Professor Young Suk Park
Keywords: Pazopanib, GEP-NETs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1059 Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era
Introduction: We have conducted molecular profiling through high-throughput molecular test as part of clinical practice for patients with advanced gastrointestinal (GI) cancer, or rare cancer including gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Seung Kim
Authors: Kim S, Yoo K, Jung K, Lee S, ...
#832 The Role of Plasma Chromogranin A as Assessment of Treatment Response in Grade 1-3 Non-Functioning Gastroenteropancreatic (GEP) Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is considered to be of value not only in diagnosis but also in monitoring the disease response to treatment. However, only a few studies have been published on this issue.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Professor Young Park
Authors: Park Y, Kim S, Lee J, Park S, ...
#1268 The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Introduction: Programmed death-ligand 1 (PD-L1), which is expressed on many cancer cells, interacts with PD1 expressed on the surface of T cells, inhibiting the T cells and blocking the antitumor immune response.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Seung Kim
Authors: Kim S, Park Y, ...
Keywords: PD-L1, GEP-NETs
#1580 The Impact of the Pathologic Differentiation (Well or Poorly) and the Degree of Ki-67 Index in Patients with Metastatic WHO Grade 3 GEP-NETs
Introduction: There is few data for the treatment-outcome with etoposide plus platinum between well differentiated and poorly differentiated metastatic grade 3 GEP-NEC.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: Seung Kim
Authors: Kim S, Park Y, ...
Keywords: Ki67 index
#432 Ten Years of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Evolution of Classification and Correlation with Follow-up in 50 Patients
Introduction: In the last decade, GEP-NET nomenclature has been twice reviewed. The 2000 WHO classification had poor prognostic power in well-differentiated (WD) neoplasms which led to the introduction of two new important parameters: grade and stage, by ENETS; the former became part of the new 2010 WHO classification.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Diego Ferone